Indian Company Master Data Made Simple
Search:
MCA
GSTIN
LEI
Udyam
Directors
36+ lakh companies in our registry
Glenmark Pharmaceuticals Limited
Incorporated in 1977, Glenmark Pharmaceuticals Limited has a history spanning 4 decades. The company’s Corporate Identification Number is L24299MH1977PLC019982; registration no. 19982. Glenmark Pharmaceuticals Limited is registered as company limited by shares. Its authorized share capital is ₹277.00 crore. Glenmark Pharmaceuticals Limited’s paid-up capital stands at ₹28.22 crore.
Its primary business activity involves manufacture of other chemical products. Its registered office is located in Mumbai. Its registered address is B-2mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India, 400026. Currently, the company’s operational status is active. Glenmark Pharmaceuticals Limited holds PAN AAACG2207L. The company has been issued the Legal Entity Identifier code 335800WKECZXIIT9GK20. For correspondence, the registered email address is complianceofficer@glenmarkpharma.com. The company’s top executive team comprises V S Mani (CFO).
Company Overview
- CIN
- Date of Incorporation
- 17/11/1977
- Company Status
- Active
- RoC
- Mumbai
- Registration Number
- Balance sheet date
- 31/03/2024
- Company Category
- Company limited by shares
- Company Sub Category
- Non-government company
- Listed in Stock Exchange
- Yes
- Class of Company
- Public Limited Company
- LEI Number
- LEI Status
- Issued
- Authorized Capital
- ₹2,77,00,00,000.00
- Paid up Capital
- ₹28,21,88,156.00
- Activity
- Manufacture of other chemical products
- complianceofficer@glenmarkpharma.com
- PAN
GST Numbers
| State | GST Number | Status |
|---|---|---|
| Assam | 18AAACG2207L1ZR | Inactive |
| 18AAACG2207L2ZQ | Inactive | |
| 18AAACG2207L3ZP | Inactive | |
| Andhra Pradesh | 37AAACG2207L1ZR | Inactive |
| Bihar | 10AAACG2207L1Z7 | Inactive |
| Chandigarh | 04AAACG2207L1Z0 | Inactive |
| Chhattisgarh | 22AAACG2207L1Z2 | Inactive |
| Daman and Diu | 25AAACG2207L1ZW | Inactive |
| Delhi | 07AAACG2207L1ZU | Active |
| Gujarat | 24AAACG2207L1ZY | Active |
ISIN Numbers
| ISIN | Security | Interest Rate | Maturity Date | FISN | CFI |
|---|---|---|---|---|---|
| IN8935A01018 | GLENMARK PHARMACEUTICALS LIMITED EQ LISTING/TRADING APPROVAL AWAITED | - | 12/10/2026 | GLENMARK PHARMA/SH VTG | ESVUFN |
| INE935A01035 | GLENMARK PHARMACEUTICALS LIMITED EQ NEW FV RE.1/- | - | 12/10/2026 | GLENMARK PHARMA/SH VTG | ESVUFN |
| IN9935A01058 | GLENMARK PHARMACEUTICALS LIMITED PP RE.1/- | - | 12/10/2026 | GLENMARK PHARMA/SH VTG PP | ESVUPN |
Balance Sheet
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Net PPE | ₹4,34,377.00L | ₹3,88,785.20L | ₹3,56,782.20L | ₹4,22,147.40L | ₹0.00L |
| Goodwill | ₹8,286.40L | ₹7,026.60L | ₹6,735.90L | ₹7,361.90L | ₹0.00L |
| Gross PPE | ₹7,14,512.00L | ₹6,68,132.70L | ₹6,06,021.90L | ₹6,48,562.30L | ₹0.00L |
| Inventory | ₹3,43,077.60L | ₹3,02,853.00L | ₹2,51,305.10L | ₹2,37,362.00L | ₹0.00L |
| Total Debt | ₹59,352.70L | ₹2,47,266.70L | ₹1,23,093.00L | ₹4,60,788.10L | ₹0.00L |
| Common Stock | ₹2,822.00L | ₹2,821.90L | ₹2,821.90L | ₹2,821.70L | ₹0.00L |
| Current Debt | ₹0.00L | ₹1,68,149.50L | ₹99,059.60L | ₹49,558.20L | ₹0.00L |
| Share Issued | ₹2,822.01L | ₹2,821.88L | ₹2,821.88L | ₹2,821.68L | ₹0.00L |
| Total Assets | ₹19,90,787.60L | ₹16,04,955.40L | ₹14,35,862.40L | ₹19,37,167.60L | ₹0.00L |
| Capital Stock | ₹2,822.00L | ₹2,821.90L | ₹2,821.90L | ₹2,821.70L | ₹0.00L |
| Long Term Debt | ₹0.00L | ₹51,270.00L | ₹0.00L | ₹3,85,213.80L | ₹0.00L |
| Current Assets | ₹11,29,970.90L | ₹9,29,546.50L | ₹7,42,808.20L | ₹10,72,552.70L | ₹0.00L |
| Prepaid Assets | ₹82,062.30L | ₹64,238.10L | ₹56,888.10L | ₹64,122.80L | ₹0.00L |
| Working Capital | ₹4,92,328.30L | ₹3,32,844.10L | ₹1,60,949.50L | ₹5,62,047.10L | ₹0.00L |
| Invested Capital | ₹10,51,210.90L | ₹11,04,363.60L | ₹8,83,852.30L | ₹13,82,164.30L | ₹0.00L |
| Other Properties | ₹3,88,956.90L | ₹3,31,936.60L | ₹3,11,815.30L | ₹3,90,416.30L | ₹0.00L |
| Retained Earnings | ₹9,88,164.90L | ₹8,79,853.90L | ₹7,87,044.90L | ₹9,45,703.90L | ₹0.00L |
| Common Stock Equity | ₹10,51,210.90L | ₹8,84,944.10L | ₹7,84,792.70L | ₹9,47,392.30L | ₹0.00L |
| Net Tangible Assets | ₹8,00,588.10L | ₹7,38,914.20L | ₹6,51,336.20L | ₹7,05,762.20L | ₹0.00L |
| Tangible Book Value | ₹8,00,588.10L | ₹7,38,914.20L | ₹6,51,336.20L | ₹7,05,762.20L | ₹0.00L |
| Current Liabilities | ₹6,37,642.60L | ₹5,96,702.40L | ₹5,81,858.70L | ₹5,10,505.60L | ₹0.00L |
| Long Term Provisions | ₹17,661.40L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Stockholders Equity | ₹10,51,210.90L | ₹8,84,944.10L | ₹7,84,792.70L | ₹9,47,392.30L | ₹0.00L |
| Other Equity Interest | ₹3,401.20L | ₹906.50L | ₹2,491.10L | ₹1,761.70L | ₹0.00L |
| Total Capitalization | ₹10,51,210.90L | ₹9,36,214.10L | ₹7,84,792.70L | ₹13,32,606.10L | ₹0.00L |
| Ordinary Shares Number | ₹2,822.01L | ₹2,821.88L | ₹2,821.88L | ₹2,821.68L | ₹0.00L |
| Other Intangible Assets | ₹2,42,336.40L | ₹1,39,003.30L | ₹1,26,720.60L | ₹2,34,268.20L | ₹0.00L |
| Other Non Current Assets | ₹0.20L | ₹17,903.10L | ₹14,923.10L | ₹15,385.70L | ₹0.00L |
| Total Non Current Assets | ₹8,60,816.70L | ₹6,75,408.90L | ₹6,93,054.20L | ₹8,64,614.90L | ₹0.00L |
| Cash And Cash Equivalents | ₹1,17,470.90L | ₹1,67,570.70L | ₹1,65,827.00L | ₹1,15,920.30L | ₹0.00L |
| Construction In Progress | ₹45,420.10L | ₹56,848.60L | ₹44,966.90L | ₹1,09,220.10L | ₹0.00L |
| Accumulated Depreciation | -₹2,80,135.00L | -₹2,79,347.50L | -₹2,49,239.70L | -₹2,26,414.90L | ₹0.00L |
| Additional Paid In Capital | ₹1,70,731.60L | ₹1,70,655.80L | ₹1,70,655.80L | ₹1,70,536.00L | ₹0.00L |
| Other Short Term Investments | ₹2,613.70L | ₹1,575.90L | ₹1,213.10L | ₹1,408.60L | ₹0.00L |
| Other Non Current Liabilities | ₹1,53,613.70L | ₹0.00L | ₹169.10L | ₹132.90L | ₹92.00L |
| Machinery Furniture Equipment | ₹3,82,521.30L | ₹3,63,506.90L | ₹3,28,297.00L | ₹3,26,383.60L | ₹0.00L |
| Goodwill And Other Intangible Assets | ₹2,50,622.80L | ₹1,46,029.90L | ₹1,33,456.50L | ₹2,41,630.10L | ₹0.00L |
| Total Equity Gross Minority Interest | ₹10,51,179.30L | ₹8,84,907.00L | ₹7,84,754.70L | ₹9,83,925.90L | ₹0.00L |
| Total Liabilities Net Minority Interest | ₹9,39,608.30L | ₹7,20,048.40L | ₹6,51,107.70L | ₹9,53,241.70L | ₹0.00L |
| Current Debt And Capital Lease Obligation | ₹10,722.00L | ₹1,77,375.70L | ₹1,07,923.90L | ₹57,862.10L | ₹0.00L |
| Long Term Debt And Capital Lease Obligation | ₹48,630.70L | ₹69,891.00L | ₹15,169.10L | ₹4,02,926.00L | ₹0.00L |
| Cash Cash Equivalents And Short Term Investments | ₹1,20,084.60L | ₹1,69,146.60L | ₹1,67,040.10L | ₹1,17,328.90L | ₹0.00L |
| Total Non Current Liabilities Net Minority Interest | ₹3,01,965.70L | ₹1,23,346.00L | ₹69,249.00L | ₹4,42,736.10L | ₹0.00L |
Cash Flow
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 |
|---|---|---|---|---|
| Net Income | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,50,166.80L | ₹29,724.50L |
| Free Cash Flow | ₹2,08,732.10L | -₹1,57,831.50L | -₹1,16,382.20L | ₹1,762.90L |
| Changes In Cash | -₹54,695.30L | -₹3,845.60L | ₹38,932.20L | ₹1,944.50L |
| End Cash Position | ₹1,17,470.90L | ₹1,67,570.70L | ₹1,65,827.00L | ₹1,44,302.60L |
| Financing Cash Flow | -₹2,70,874.80L | ₹78,704.50L | -₹3,90,612.70L | -₹7,745.60L |
| Investing Cash Flow | -₹1,28,323.30L | ₹209.40L | ₹4,56,089.30L | -₹52,849.10L |
| Operating Cash Flow | ₹3,44,502.80L | -₹82,759.50L | -₹26,544.40L | ₹62,539.20L |
| Capital Expenditure | -₹1,35,770.70L | -₹75,072.00L | -₹89,837.80L | -₹60,776.30L |
| Beginning Cash Position | ₹1,67,570.70L | ₹1,65,827.00L | ₹1,44,302.60L | ₹1,41,052.60L |
| Issuance Of Capital Stock | ₹75.90L | ₹0.00L | ₹120.00L | ₹0.00L |
| Other Cash Adjustment Outside Changein Cash | -₹0.40L | ₹0.10L | -₹19,175.70L | ₹66.80L |
Income Statement
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 |
|---|---|---|---|---|
| EBIT | ₹2,19,347.10L | ₹1,60,627.40L | ₹55,246.40L | ₹58,887.80L |
| Ebit | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| EBITDA | ₹2,76,695.20L | ₹2,09,228.40L | ₹1,18,327.40L | ₹1,20,014.60L |
| Basic EPS | ₹0.00L | ₹0.00L | -₹0.00L | ₹0.00L |
| Net Income | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,50,166.80L | ₹29,724.50L |
| Diluted EPS | ₹0.00L | ₹0.00L | -₹0.00L | ₹0.00L |
| Gross Profit | ₹11,59,749.60L | ₹8,38,849.40L | ₹6,75,641.60L | ₹6,84,533.30L |
| Pretax Income | ₹1,98,474.60L | ₹1,39,920.90L | ₹3,649.50L | ₹23,984.20L |
| Tax Provision | ₹62,279.40L | ₹35,206.70L | ₹1,86,734.50L | ₹32,940.30L |
| Total Revenue | ₹16,71,140.30L | ₹13,14,583.60L | ₹11,63,545.60L | ₹11,43,193.80L |
| Cost Of Revenue | ₹5,11,390.70L | ₹4,75,734.20L | ₹4,87,904.00L | ₹4,58,660.50L |
| Total Expenses | ₹12,68,807.70L | ₹11,27,736.90L | ₹11,00,438.10L | ₹10,35,306.40L |
| Interest Income | ₹4,132.90L | ₹4,393.50L | ₹617.60L | ₹700.00L |
| Interest Expense | ₹20,872.50L | ₹20,706.50L | ₹51,596.90L | ₹34,903.60L |
| Operating Income | ₹4,02,332.60L | ₹1,86,846.70L | ₹63,107.50L | ₹1,07,887.40L |
| Tax Rate For Calcs | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Income Tax Expense | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Normalized EBITDA | ₹5,05,742.60L | ₹2,46,819.90L | ₹2,10,034.90L | ₹1,97,331.80L |
| Normalized Income | ₹2,93,359.65L | ₹1,32,842.48L | -₹1,25,704.35L | ₹37,150.44L |
| Operating Expense | ₹7,57,417.00L | ₹6,52,002.70L | ₹6,12,534.10L | ₹5,76,645.90L |
| Operating Revenue | ₹16,71,140.30L | ₹13,14,583.60L | ₹11,63,545.60L | ₹11,43,193.80L |
| Net Interest Income | -₹16,739.60L | -₹16,313.00L | -₹50,979.30L | -₹34,203.60L |
| Total Unusual Items | -₹2,29,047.40L | -₹37,591.50L | -₹91,707.50L | -₹77,317.20L |
| Basic Average Shares | ₹2,822.00L | ₹2,821.88L | ₹2,821.62L | ₹2,821.68L |
| Diluted Average Shares | ₹2,822.90L | ₹2,822.10L | ₹2,821.79L | ₹2,821.68L |
| Other Operating Expenses | ₹1,60,800.30L | ₹1,40,549.60L | ₹1,31,907.90L | ₹1,16,117.70L |
| Reconciled Depreciation | ₹57,348.10L | ₹48,601.00L | ₹63,081.00L | ₹61,126.80L |
| Total Operating Expenses | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Reconciled Cost Of Revenue | ₹5,11,390.70L | ₹4,75,734.20L | ₹4,87,904.00L | ₹4,58,660.50L |
| Rent Expense Supplemental | ₹6,695.50L | ₹5,150.80L | ₹6,261.20L | ₹5,559.90L |
| Tax Effect Of Unusual Items | -₹71,872.85L | -₹9,458.72L | -₹27,512.25L | -₹23,195.16L |
| Interest Income Non Operating | ₹4,132.90L | ₹4,393.50L | ₹617.60L | ₹700.00L |
| Selling And Marketing Expense | ₹1,43,179.30L | ₹1,27,051.50L | ₹1,09,227.30L | ₹1,13,719.60L |
| Interest Expense Non Operating | ₹20,872.50L | ₹20,706.50L | ₹51,596.90L | ₹34,903.60L |
| Net Income Common Stockholders | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,50,166.80L | ₹29,724.50L |
| Net Income Continuous Operations | ₹1,36,195.20L | ₹1,04,714.20L | -₹1,83,085.00L | -₹8,956.10L |
| Diluted NIAvailto Com Stockholders | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,50,166.80L | ₹29,724.50L |
| General And Administrative Expense | ₹44,012.40L | ₹33,277.30L | ₹25,698.00L | ₹29,484.80L |
| Selling General And Administration | ₹1,87,191.70L | ₹1,60,328.80L | ₹1,34,925.30L | ₹1,43,204.40L |
| Otherunder Preferred Stock Dividend | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Total Unusual Items Excluding Goodwill | -₹2,29,047.40L | -₹37,591.50L | -₹91,707.50L | -₹77,317.20L |
| Net Non Operating Interest Income Expense | -₹16,739.60L | -₹16,313.00L | -₹50,979.30L | -₹34,203.60L |
| Net Income Including Noncontrolling Interests | ₹1,36,195.20L | ₹1,04,714.20L | -₹1,43,352.20L | ₹37,740.00L |
| Net Income From Continuing And Discontinued Operation | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,50,166.80L | ₹29,724.50L |
| Net Income From Continuing Operation Net Minority Interest | ₹1,36,185.10L | ₹1,04,709.70L | -₹1,89,899.60L | -₹16,971.60L |
Company Performance (FY23–FY26)
₹16.7 K Cr₹12.5 K Cr₹8.4 K Cr₹4.2 K Cr₹0
FY23FY24FY25FY26
Directors
| Appointment | Director name | DIN | Designation | |
|---|---|---|---|---|
| 12/10/1998 | Glenn Mario Saldanha | 00050607 | Managing Director | View other directorships |
| 16/05/2007 | Cherylann Maria Pinto | 00111844 | Whole-time director | View other directorships |
| 14/08/2009 | Blanche Saldanha Elizabeth | 00007671 | Director | View other directorships |
| 02/02/2017 | Harish Vinayak Kuber | *****8790R | Company Secretary | |
| 31/03/2017 | Rajesh Vasudeo Desai | 00007960 | Director | View other directorships |
| 16/11/2017 | V S Mani | *****5727N | CFO | |
| 29/05/2018 | V S Mani | 01082878 | Whole-time director | View other directorships |
| 01/04/2019 | Sona Saira Ramasastry | 08398547 | Director | View other directorships |
| 14/08/2020 | Dipankar Bhattacharjee | 08770548 | Director | View other directorships |
| 10/02/2023 | Vijayalakshmi Iyer | 05242960 | Director | View other directorships |
Business Network
CompanyDirectorNot on WeeDooBoard seatKey rolePast seatOwnership
Directors 10
- Glenn Mario SaldanhaManaging Director
- V S ManiWhole-time director
- Cherylann Maria PintoWhole-time director
- Vijayalakshmi IyerDirector
- Dipankar BhattacharjeeDirector
- Sona Saira RamasastryDirector
- Rajesh Vasudeo DesaiDirector
- Blanche Saldanha ElizabethDirector
- V S ManiCFO
- Harish Vinayak KuberCompany Secretary
Subsidiaries 4
- Общество С Ограниченной Ответственностью "гленмарк Импэкс"Direct
- Glenmark Holding SaDirect
- Glenmark Therapeutics Inc., UsaUltimate
- Glenmark Pharmaceuticals Inc., UsaUltimate
Latest Documents
Category:
| Date | Title | Size |
|---|---|---|
| 19/11/2024 | Form MGT-7-19112024_signed | - |
| 25/10/2024 | Form AOC-4(XBRL)-25102024 | - |
| 26/03/2024 | Form Addendum to AOC-4 CSR-26032024_signed | - |
Similar Companies
| Company | CIN | Address |
|---|---|---|
| Bhatia Colour Chem Limited | L24290GJ2021PLC127878 | Plot No. A/2/12, Road No. 1, Udhana Udyog Nagar Sangh Udhna, Surat, Surat, Gujarat, India, 394210 |
| Maitreya Medicare Limited | L24290GJ2019PLC107298 | Nr Someshwara Char Rasta, Um Road, Surat, Surat City, Gujarat, India, 395007 |
| National Peroxide Limited | L24290MH2020PLC342890 | Neville House, J.n. Heredia Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India, 400001 |
| Senores Pharmaceuticals Limited | L24290GJ2017PLC100263 | 1101 To 1103, 11th Floor, South Tower, One 42 Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Ahmedabad, Gujarat, India, 380054 |
| Sree Maruthi Marine Industries Limited | L24290TN1973PLC006441 | No. 1/220, Kamaraj Street Kelambakkam, Kancheepuram, Tamil Nadu, India, 603103 |
Direct/Ultimate Children
| Type | Legal Name | LEI code |
|---|---|---|
| Direct | Общество С Ограниченной Ответственностью "гленмарк Импэкс" | 253400Q24T70CT4GBC85 |
| Direct | Glenmark Holding Sa | 506700E62GR12JRI9878 |
| Ultimate | Glenmark Therapeutics Inc., Usa | 254900JFDC6JEPHQF612 |
| Ultimate | Glenmark Pharmaceuticals Inc., Usa | 549300P2PTIYYGIM8U12 |
Address
B-2mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India, 400026
Frequently Asked Questions
What is the incorporation date of Glenmark Pharmaceuticals Limited?
The incorporation date of Glenmark Pharmaceuticals Limited is 17/11/1977.
What is the authorized share capital and paid-up capital of Glenmark Pharmaceuticals Limited?
The authorized share capital of Glenmark Pharmaceuticals Limited is ₹2,77,00,00,000.00. The paid-up capital is ₹28,21,88,156.00.
Who are the current board members & directors of Glenmark Pharmaceuticals Limited?
The current board member of Glenmark Pharmaceuticals Limited are:
- Glenn Mario Saldanha
- V S Mani
- Sona Saira Ramasastry
- Rajesh Vasudeo Desai
- Blanche Saldanha Elizabeth
- Cherylann Maria Pinto
- Dipankar Bhattacharjee
- Vijayalakshmi Iyer
What is the registered address of Glenmark Pharmaceuticals Limited?
The registered address of Glenmark Pharmaceuticals Limited is B-2mahalaxmi Chambers22 Bhulabhai Desai Road Mahalaxmi, Mumbai, Maharashtra, India, 400026.
What is the Corporate Identification Number of Glenmark Pharmaceuticals Limited?
The Corporate Identification Number of Glenmark Pharmaceuticals Limited is L24299MH1977PLC019982.